Understanding GLP-1 Medications
GLP-1 medications, such as semaglutide and liraglutide, are gaining popularity for their role in managing blood sugar levels and aiding…
Tag: GLP-1
The Unexpected Side Effects of GLP-1 Drugs Like Ozempic
While medications like Ozempic (semaglutide) and Wegovy have gained massive popularity for their remarkable weight loss and diabetes management abilities,…
Groundbreaking Study Shows Semaglutide Significantly Reduces Kidney Disease, Heart Risks and Mortality in Diabetics
Results from a major clinical trial revealed the diabetes drug semaglutide (Ozempic) significantly reduced the risk of serious kidney disease…
Ozempic and Wegovy Linked to Increased Risk of Stomach Paralysis
Popular weight loss medications like Ozempic (semaglutide) and Wegovy have been associated with higher rates of a potentially serious condition…
Zealand’s Dual GLP-1/GLP-2 Agonist Shows Modest Weight Loss at Low Doses
Biotech company Zealand Pharma reported early clinical trial results for their experimental drug ZP2929, a dual agonist targeting both the…
‘Ozempic Babies’ Concerns? Study Finds High GLP-1 Drug Use Among Young Women
A new study has revealed that over 75% of young adults aged 16-44 taking medications like Ozempic, Wegovy and Mounjaro…
Nestle Hopes to Cash In on Ozempic Craze with Weight Loss Frozen Meals
Food giant Nestle is aiming to capitalize on the surge in use of anti-obesity medications like Ozempic and Wegovy. The…
Weighing the Costs and Side Effects of Popular Weight Loss Drugs
There are high costs and potential side effects of the new generation of weight loss medications like semaglutide (Wegovy) and…
Muscle-Preserving Drugs in Development to Complement Weight Loss from GLP-1 Medications
As GLP-1 drugs like semaglutide (Wegovy) and tirzepatide (Zepbound) are producing unprecedented weight loss, concern has arisen about the proportion…
Lilly Doubles Down on Tirzepatide with $8 Billion Indiana Manufacturing Megaplant
Eli Lilly and Company is investing another $5.3 billion to expand its manufacturing capacity for tirzepatide, the company’s new diabetes/obesity…
